Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
5:36
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Non-Hodgkin Lymphoma Similar Videos
-
Loretta Nastoupil, MD; The University of Texas MD Anderson Cancer Center; 5Live #ASH21
6:24
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Matthew Lunning, DO, FACP; University of Nebraska Medical Center; 5Live #ASH21
4:55
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Appropriate indications and methods of administration of CNS prophylaxis in aggressive NHL_Victor Orellana-Noia, MD; #DDHO2021
1:36